While up to 8 million French people live with migraines resistant to traditional treatments, new approaches are revolutionizing treatment. Behind these scientific advances, there are above all suspended lives which could, little by little, resume their course. A BBC article takes stock of the latest advances.
An invisible illness, disrupted lives
There are millions of people in France living with the silent anxiety of the next crisis. Migraine is not just pain: it sometimes imposes isolation, darkness, the sudden cessation of work or social life. When traditional treatments fail, some patients see their daily lives become fragmented.
Worldwide, more than a billion people are affected by migraine. Among them, 1 to 2% develop a chronic form, defined by at least 15 days of headache per month — a level of suffering that profoundly transforms the quality of life.
Faced with this reality, research has intensified. And for the first time in decades, neurologists are speaking of a historic turning point.
“It’s a truly incredible time to treat migraine right now.”estimates Narayan Kissoon, of the Mayo Clinic, interviewed by the BBC.
This change in times is based on a better understanding of the migraine brain. For the first time, research directly targets the biological mechanisms of pain.
Targeting the pain signal: the revolution in anti-CGRP treatments
At the heart of new therapeutic strategies, a key player: the CGRP peptide. This molecule dilates blood vessels and stimulates the nerves in the skull, helping to trigger migraine pain.
Recent treatments aim to block this signal using injectable antibodies, administered monthly or quarterly; or an oral treatment, atogepant, intended for patients with at least four migraine days per month.
The results of these CGRP antagonists are encouraging but nuanced: around half of the patients see their number of migraine days decrease significantly (we call them “super-responders”). For others, the benefit remains modest. A 2020 analysis of 11 separate studies and more than 4,000 patients concluded that there was a reduction of 1.5 migraine days per month. A reminder that migraine remains a complex and multifactorial disease.
Botox for Chronic Migraines That Poison You
At the same time, a more unexpected treatment emerged: Botox. Discovered by chance in patients treated for cosmetic reasons, it subsequently demonstrated a preventive effect in adults suffering from chronic resistant migraine.
The protocol is strict: around thirty injections distributed over the forehead, temples, neck and shoulders, every three months. In some severely affected patients, the frequency of attacks can be halved.
Treatment remains reserved for specialists, particularly due to possible contraindications, such as certain neuromuscular diseases or a short-term pregnancy plan.
But what to do when medications fail or become difficult to tolerate? Another, more mechanical path now opens up unexpected perspectives.
Neuromodulation and mechanical innovations: hope differently
Neuromodulation offers a different approach: instead of acting chemically, it directly modifies nerve signals.
Among the existing devices: electrostimulation bands of the trigeminal nerve or bracelets or necklaces sending impulses to the neck
Other avenues are still emerging, sometimes with a partly mysterious pain-relieving mechanism. Teams are testing an intranasal device: a small balloon inserted into the nostril, which vibrates on contact with the nerves. The first results on pain are encouraging, but remain preliminary.
These solutions remain expensive and still not widely used. Above all, they are part of global care. Because migraine must be considered as a chronic illness requiring a personalized strategy. As such, sleep hygiene, regular physical activity, relaxation, meditation or cognitive therapies now complete the therapeutic arsenal.
A revolution without a miracle — but with a new horizon
The migraine isn’t going away yet. And not all patients respond to new treatments. But a profound transformation is underway: migraine is finally understood as a complex neurological disease, requiring multiple and individualized approaches.
For patients, these advances don’t just mean fewer days of pain. They offer something more fragile — and often more precious: the possibility of planning, of anticipating, of regaining a little control.